COLL vs NBIX: fair value comparison
Collegium Pharmaceutical, Inc. and Neurocrine Biosciences, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COLL currently sits closer to the top of our discount ranking. NBIX carries the stronger quality grade.
| COLL | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $24.00 | $156.76 |
| 12-month range | $24.00–$47.11 | $131.78–$167.77 |
| Sector rank | #16 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: COLL fair value analysis · NBIX fair value analysis